CrisprBits Unveils State-of-the-Art CRISPR Gene Editing Lab in Bengaluru

Takara Bio Acquires Curio Bioscience, Advancing Leadership in Spatial Genomics

Tempus AI Launches FDA-Approved xT CDx for Comprehensive Solid Tumor Profiling

FDA Accepts Eisai’s Biologics License Application for LEQEMBI® Subcutaneous Autoinjector for Alzheimer’s Disease

Paige’s FullFocus™ Digital Pathology Viewer Receives FDA 510(k) Clearance for Expanded Compatibility

Grifols, MJFF Launch Chronos-PD to Identify Early Parkinson’s Biomarkers

Gates Foundation Invests $50M in Tessera’s In Vivo Gene-Editing Therapy for Sickle Cell Disease

GSK Acquires IDRx for $1 Billion to Advance Precision Therapy for GIST

Scipher Medicine and Roivant Partner to Advance Precision Medicine in Rheumatology

Roche Secures FDA Clearance for VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail to Enhance B-Cell Lymphoma Diagnosis

Illumina Launches Pilot Proteomics Program with UK Biobank and Industry Partners

NavDx Test Expands Availability for Enhanced Surveillance in HPV+ Anal Cancer Patients

QIAGEN Enhances QIAcuity Digital PCR with Expanded Multiplexing Capabilities

Boehringer Ingelheim Licenses Synaffix’s ADC Technology to Advance Cancer Therapies

AIG Hospitals to Launch ₹800 Crore Oncology Centre with South-East Asia’s First Dynamic ARC Proton Therapy

Home
/
update
/
details

Helio Genomics and Halub Medical Announce Partnership to Launch HelioLiver Dx in GCC and Middle East

NextEdge Admin

26 Oct 2024

2 min 54 sec

Halub Medical,hepatocellular carcinoma,oncology

Helio Genomics, an AI-driven biotechnology company specializing in cancer diagnostics, has partnered with Halub Medical Co. to commercialize *HelioLiver Dx* in Saudi Arabia and the Gulf Cooperation Council (GCC) region. The test, designed for early detection of hepatocellular carcinoma (HCC), is set to launch in Q1 2025, with projected revenues for Helio exceeding $10 million in the first year.

“We are honored to partner with Halub Medical, a leading healthcare provider in the region,” said Shu Li, PhD, Founder and Executive Chairman of Helio Genomics. “With non-alcoholic fatty liver disease (NAFLD) affecting up to 30% of the global population, HelioLiver Dx offers a critical tool to improve liver cancer screening.”

Halub Medical’s Chairman, Sheikh Ahmed Almalki, highlighted that HelioLiver Dx demonstrates four times better sensitivity than ultrasound, the current standard for HCC surveillance, and promises nine times higher patient adherence with its blood-based approach. The test is based on pivotal trials conducted by leading U.S. medical institutions, including Stanford Medical Centers.

Dr. Talal Almalki, CEO of Saudi Arabia’s Health Cluster, emphasized the potential for further collaboration. “This partnership introduces world-class AI-based diagnostics to the Health Cluster, enabling better screening and opening the door for new co-developed tests.”

*HelioLiver Dx* analyzes cell-free DNA (cfDNA), methylation patterns, serum protein markers, and demographic data for accurate early-stage HCC detection. The test received a CPT PLA code from the American Medical Association in October 2022, facilitating Medicare coverage in the U.S. Helio Genomics also submitted a PMA application to the FDA in 2024 for full regulatory approval.

Halub Medical Co., headquartered in Taif, specializes in distributing advanced diagnostic solutions and aesthetic services across the GCC. In addition to diagnostics, the company offers dermatology treatments, laser therapies, and a rehabilitation center, enhancing healthcare across the region.